WHO WE ARE

Creative Medical Technology Holdings, Inc.

Ticker Symbol CELZ

Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company committed to improving patient lives in the areas of Immunology, Urology, Neurology and Orthopedics.

Creative Medical Technology Holdings, Inc. (CELZ) is focused on regenerative medical solutions for unmet Immunological, Urological, Neurological and Orthopedic needs. We have developed an extensive intellectual property portfolio utilizing stem cells and interrelated technologies for the treatment of multiple indications and commercialized complete patented and trademarked protocols for erectile dysfunction under the CaverStem® brand and the FemCelz® brand for the treatment of female sexual dysfunction. Our StemSpine® technology has undergone a pilot study and is prepared for commercialization of it’s autologous (patients own stem cells) program with the vision of progressing it’s patented allogenic (donor cells) program through FDA clinical trial. CELZ is also breaking new ground with its ImmCelz® technology for the treatment of multiple indications. Our team consists of leading physicians and scientists specializing in regenerative medicine. Our “science-first” approach to procedures ensures that all of our technology is proven to be both safe and effective.

The Creative Medical Technology Holdings Difference
  • Commercialized Procedures (CaverStem® and FemCelz®)

  • Extensive Patent Portfolio

  • Key Relationships With Leading Scientists and Physicians

  • Validated Safety and Efficacy

Intellectual Property

Creative Medical Technology Holdings has developed/acquired a robust intellectual property (IP) portfolio related to the utilization of stem cells to improve patient lives in the areas of Urology, Neurology and Orthopedics.

This IP portfolio positions us at the forefront of the regenerative medicine industry (set to grow to $39Bn by 2023). We plan to commercialize these products on our own and in collaboration with strategic partners.

Areas Patent Description
Urology US20180015127A1 Methods for Treatment of Premature Ovarian Failure and Ovarian Aging Using Regenerative Cells
Urology US8372797B2 Treatment of Erectile Dysfunction by Stem Cell Therapy
Urology US20180325959A1 Methods of Treating Erectile Dysfunction Using Regenerative Cells and Therapeutic Energy Treatments
Neuro/Oncology US20190022147A1 Treatment of Glioma by Amniotic Fluid Stem Cells and Exosomes Derived Thereof
Neurology US20180340145A1 Generation of Autologous Immune Modulatory Cells for Treatment of Neurological Conditions
Stem Cells US7569385B2 Multipotent Amniotic Fetal Stem Cells
Orthopedics US20180344899A1 Enhancement of Nucleus Pulposus Regeneration by Enhanced Perfusion of Perispinal Area by Combination Drug, Gene and Cellular Therapies
Orthopedics US20180360882A1 Perispinal Perfusion by Administration of T Regulatory Cells Alone or in Combination with Angiogenic Cell Therapies
Orthopedics US9598673B2 Treatment of Disc Degenerative Disease
Immunotherapy US63123380 Induction of Infectious Tolerance by Ex Vivo Reprogrammed Immune Cells
Immunotherapy US62510,203. Generation of Autologous Immune Modulatory Cells for Treatment of Neurological Conditions
Immunotherapy US63132472 Treatment of Heart Failure and/or Post Infarct Pathological Remodeling by Ex Vivo Reprogrammed Immune Cells
Immunotherapy US63138776 Treatment of Diabetes Using Immune Cells Reprogrammed Ex Vivo by Regenerative Cells
Immunotherapy US63138576 Treatment of Liver Failure by Ex Vivo Reprogrammed Immune Cells
Immunotherapy US63149671 Treatment of Chronic Rejection and Concurrent Induction of Transplantation Tolerance by Ex Vivo Altered Immune Cells

Timothy Warbington

Chief Executive Officer

Donald Dickerson

Chief Financial Officer

Thomas Ichim PhD

Chief Scientific Officer

Timothy Warbington

Donald Dickerson

Thomas Ichim PhD

Amit Patel MS MD

Timothy Henry  MD

Director of Cardiology, Cedars-Sinai Heart Institute. Dr. Henry’s experience also includes Director of Research at Minneapolis Heart Institute Foundation.

Boris Reznik A.S. M.S. Ph.D. – SAB

Boris Reznik is the Chairman of Venvalo Group. During his career spanning four decades, Dr. Reznik founded and built technology companies into market leaders, managed high growth, profitable enterprises and successfully dealt with both Fortune 500 and emerging companies as clients and partners. He has been a lead or co-investor in multiple technology-based companies and has participated in many public and private fundings and mergers and acquisitions of technology-based companies, ranging from Millions to Billions.

Santosh Kesari, MD, PhD

Director, Neuro-oncology;  Chair and Professor, Department of Translational Neurosciences and Neurotherapeutics, John Wayne Cancer Institute

Amit Patel MS MD

Cardiac surgeon, former Associate
Professor and Director of Clinical
Regenerative Medicine and Tissue
Engineering at the University of Utah.
Dr. Patel has pioneered break-through therapies using stem cells and is a world leader in stem cell therapies.

Our Pipeline
Product
Description
Preclinical
Clinical
Pilot
In-Market

CaverStem®

Regenerative Stem Cell Procedure for Treatment of Erectile Dysfunction in Men

FemCelz®

Regenerative Stem Cell Procedure for Treatment of Female Sexual Dysfunction

StemSpine®

Regenerative Stem Cell Procedure for Treatment of Degenerative Disc Disease

ImmCelz®

Amniotic Fluid Derived Stem Cells for Treatment of Stroke

OvaStem®

Stem Cell Treatment for Premature Ovarian Failure

MEDIA

FACEBOOK

Creative Medical Technology Holdings Inc.

2 months 3 weeks ago

www.prnewswire.com/news-releases/creative-medical-technology-holdings-files-patent-on-prevention-of-organ-transplant-rejection-using-immcelz-301228810.html

Creative Medical Technology Holdings Inc.

2 months 3 weeks ago

We've been asked to become active again on Twitter. Excellent suggestion. We are vetting candidates for a social media position within the company. Should any

Creative Medical Technology Holdings Inc.

2 months 3 weeks ago

To our shareholders, we too are eagerly waiting for an FDA response to our IND application for the treatment of stroke. We have not received

Creative Medical Technology Holdings Inc.

2 months 4 weeks ago

finance.yahoo.com/news/creative-medical-technology-holdings-identifies-124500808.html

Creative Medical Technology Holdings Inc.

2 months 4 weeks ago

The company has received inquiries about our license for the JadiCell. As reflected in our public disclosures, CELZ does have a license for the JadiCell

Creative Medical Technology Holdings Inc.

3 months 1 week ago

finance.yahoo.com/news/creative-medical-technology-holdings-files-124500550.html

Creative Medical Technology Holdings Inc.

3 months 3 weeks ago

www.prnewswire.com/news-releases/creative-medical-technology-holdings-announces-successful-application-of-immcelz-immunotherapy-for-treatment-of-stroke-301193921.html

Creative Medical Technology Holdings Inc.

3 months 4 weeks ago

finance.yahoo.com/news/creative-medical-technology-holdings-identifies-124500811.html

CAREERS

At Creative Medical Technology Holdings, our team is committed to unlocking the full potential of regenerative medicine to improve human health.

We are always looking for talented individuals to join us in this mission.
To be considered, please email your resume to

CEO@CreativeMedicalHealth.com

Contact Us